Back

Initiation of SGLT2I during acute HF hospitalization or in the immediate period following discharge.

12 May 2024 (15:00 - 16:00)
Organised by: Logo
Congress Presentation Part of: ePosters in acute heart failure 8 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Fiyinfoluwa Fabamwo

St Vincent's University Hospital, Dublin (Ireland)

7 More presentations in this session

Presentation thumbnail
Clinical profile of the elderly patient admitted for acute heart failure in the emergency department of a tertiary hospital
Doctor D. De Almeida Fernandes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Prognostic effect of the combined use of thiazides and loop diuretics at discharge following a hospitalization for acute heart failure
Doctor A. Gasull Sandoval (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
The effect of sex on SGLT-2 antagonists and GLP-1 agonists in the treatment of heart failure: a systematic review and meta-analysis
Mr M. Philip (GB)
Abstract Slides Video
Presentation thumbnail
Thoracic fluid content as a marker of high intravenous diuretic requirements in patients hospitalized for heart failure decompensation
Doctor A. Galas (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
What clinical parameters are associated with the prescription at hospital discharge of all medications with prognostic improvement? Analysis in de novo heart failure with reduced ejection fraction
Doctor R. Lopez Vilella (Valencia, ES)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in acute heart failure 8

The Event

Event poster

Heart Failure 2024

12 May 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Initiation of sodium-glucose co-transporter-2 inhibitors in patients with heart failure in the acute medical setting
thumbnail
Congress Presentation
Early in-hospital initiation of SGLT2 inhibitors in acute decompensated heart failure
thumbnail
Congress Presentation
Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources